Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Metal ropes
Contact UsYancheng Zhongming New Materials Co., Ltd. is located in Yancheng City, Jiangsu Province.
-
Sungrow String Inverter SG 6.0 RS
Contact UsSuitable for 50Hz/60Hz grid, could be used in Asia, Africa,South America,Australia and Europe. Available for hand installation, no need for liftingmachinery assistance.
-
7000A 12V&24V Jump Starter for Truck Starting in -40C
Contact Us（*For Jump Starter ODM/OEM Solutions, secure your exclusive quotation now!）
-
Reviews
There are no reviews yet.